Meeting Minutes

Meeting Date:	July 25, 2025 at 11:00 AM Pacific Time
Meeting Place:	Teleconference (Remote) Open to the public
Members in Attendance:	Noriea, Nicholas Rastein, Daniel Ramil, Jennifer Roy, Julia
Members Not in Attendance:	Wang, Anthony Hall, David
Guests:	West, Blaine Sanchez, Santi (joined at 11:29AM)
Staff:	Hemmelgarn, Marian
Institution:	Retina Consultants San Diego - Poway

Call to Order: The meeting was called to order at 11:02 AM PT. A quorum was present.

Conflicts of Interest: None declared by voting members of the IBC.

Meeting Minutes: None.

New Business:

PI:	London, Nikolas MD, FACS
Sponsor:	Perceive Biotherapeutics, Inc.
Protocol:	PBI-AMD-002 A Phase 1/2a Study of VOY-101 in Subjects with Advanced Non-Neovascular Age-Related Macular Degeneration (JOURNEY)
Review Type:	Initial Review
NIH Guidelines:	III-C

Trial Summary: PBI-AMD-002 is an open-label, multi-center Phase I/IIa clinical trial sponsored by Perceive Biotherapeutics, Inc. and designed to assess the safety, tolerability, and efficacy of a single, unilateral intravitreal (IVT) injection of escalating dose levels of VOY-101 therapy in subjects with geographic atrophy (GA) secondary to advanced non-neovascular age-related macular degeneration (AMD). VOY-101 is a recombinant adeno-associated viral vector, AAV serotype 2, containing a transgene that encodes the truncated isoform of human Complement Factor H (hCFHT).

Biosafety Containment Level per Risk Assessment: BSL-1 plus Standard Precautions

Comments:

- The Committee reviewed the Sponsor's study documents and the comprehensive study-specific Risk Assessment which provided a thorough description of the recombinant or synthetic nucleic acid molecules ("investigational product [IP]") and the proposed clinical research involving the IP.
    - The Committee agreed that the potential risks and occupational exposure hazards associated with handling the IP in this clinical trial were well-described in the Risk Assessment.

- The Committee reviewed the Site's facility details, study-specific procedures and practices, training records, the PI's credentials and other applicable information provided by the Site for the purposes of the IBC review.
    - The Site verified that the information provided by the Chair was accurate.
    - The Site confirmed that the storage room and preparation/administration rooms are in the same building.
    - The Committee discussed the biohazard waste container in the preparation and administration room. In response to a question from the Committee, the Site noted that the white label on the lid indicates the container is used for non-sharps biohazard waste. The Committee noted that the biohazard waste container should have a biohazard label on the lid as well as the sides to be compliant with local regulations. The Site had no concerns and indicated that an updated photo would be provided.
    - The Site confirmed that preparation may occur while the participant is in the room. The Site described the manner in which the preparation takes place to minimize participant exposure. The Committee had no concerns.

Motion: A motion of Full Approval for the study at BSL-1 plus Standard Precautions was passed by majority vote. There were no abstentions on voting.

- Contingencies stated by the Committee: None

- Stipulations stated by the Committee: None

Reminder of IBC Approval Requirements.

Adjournment: 11:48 AM

Post-Meeting Pre-Approval Note: None